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1.1 Chronic Lymphocytic Leukemia (CLL) 
Chronic Lymphocytic Leukemia (CLL) is an incurable disease, and one of the most 
frequent leukemias in developed countries. CLL is most frequently diagnosed among people 
aged 65–74, the median age at diagnosis is 70. (Chronic Lymphocytic Leukemia - Cancer Stat 
Facts, b.r.)  
1.1.1 CLL Diagnosis, Prognosis, Treatment 
Chronic Lymphocytic Leukemia is characterised by the accumulation of mature and CD5-
positive B-cells – found in peripheral blood, bone marrow, spleen, and lymph nodes. CLL 
cells express following antigens CD19, CD20, and CD23 (Rozman & Montserrat, 1995). The 
most common revelation of Chronic Lymphocytic Leukemia is incidental discovery, mostly 
by routine examination. CLL is diagnosed by an elevated B-cell count in peripheral blood, 
estimated at more than 5000 B-cells per µL (Fig. 1). Which is 10-100 times higher than the 
usual concentration by a healthy person (Concentration of B cells in blood - Human Homo 
sapiens - BNID 103556, b.r.). The elevated count can be caused by other reasons e.g., 
infection. These reasons for lymphocytosis and lymphadenopathy have to be excluded, 
therefore immunophenotyping of peripheral blood is performed. In the case of 
immunophenotyping not being enough to diagnose, a biopsy of lymph nodes is executed.    
 
Fig. 1 Blood smear of bone marrow. Smudge cells, typical for chronical lymphocytic leukemia are shown in the 




An international prognostic index for patients with chronic lymphocytic leukemia 
(CLL-IPI) („An International Prognostic Index for Patients with Chronic Lymphocytic 
Leukaemia (CLL-IPI)", 2016) was created to separate patients into four risk groups with a 
different chance of survival and planning of treatment – Low risk, Intermediate risk, High 
risk, and Very high risk. Separation into these four groups was performed based on specific 
genomic changes and chromosomal aberrations. Initial and most frequent aberration is the 
deletion of the 13q chromosome, which is present in 55 % of cases and trisomy of 12 
chromosome. In more advanced stages, deletions of chromosome 11q and 17p occur (Rozman 
& Montserrat, 1995). 
Genetic and molecular biology markers can be used for identification of the risk of 
progression and survival, which is complementary to the staging system. Mutations in specific 
genes vary according to the stage of the disease, for example, TP53 aberrations specifically 
occur by aggressive disease. 
 Besides the abovementioned genetic markers the CLL progression is also 
characterised by occurence of ZAP-70, CD38 molecules and on the mutation status of IgVH. 
Where the favorable CLL stage is described by ZAP-70-, CD38-, mutated IgVH and the 
adverse CLL stage is described by expression of ZAP-70, CD38 and unmutated status of 
IgVH (Chiorazzi et al., 2005) 
Treatment 
In the early stage of the disease, asymptomatic patients are monitored without therapy 
until disease progression. Basically, clinicians follow the rule "watch and wait" 
Treatment of patients starts based on the Rai and Binet staging system and present symptoms, 
e.g., marrow failure, thrombocytopenia, unintentional weight loss. 
Different types of chemoimmunotherapy drugs are used based on the patient’s fitness level 
and presence of TP53 aberration. Treatment by a combination of drugs, such as anti-CD20 
monoclonal antibody rituximab, fludarabine, and cyclophosphamide (FCR) helps the 
treatment and prolongs survival of patients. Patients with FCR treatment achieved the longest 
median progression-free survival, which leads to chemoimmunotherapy with FCR is the first-
line standard care for physically fit patients (Cramer et al., 2016). 
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Patients with TP53 aberration have a very aggressive disease course and respond poorly to 
chemoimmunotherapy. The outcome improved with the introduction of ibrutinib, idelalisib, 
and venetoclax, all of them act independently of the p53 pathway. 
Choosing the right pathway for treatment may be difficult because of so many options. 
Therefore parameters that are considered include fitness, age, comorbidities, and genetic 
status of TP53 (Eichhorst et al., 2015). 
Duration of remission varies however, 86,1 % of patients survive 5 years after the diagnosis 
of CLL (Chronic Lymphocytic Leukemia - Cancer Stat Facts, b.r.). Patients are regularly 
monitored and when symptoms occur, second-line treatment starts. The sooner relapse 

















1.2 Characteristics of microRNAs 
MicroRNAs (miRNAs) represent single stranded non-coding RNAs (ncRNAs) found 
in all kingdoms (plants, animals and viruses) and 18-25 nucleotides long (Mashima, 2015). 
MiRNAs are evolutionarily conserved among species that underlie their importance in 
biological processes (Bartel DP et al, 2018). The function of miRNAs lies in the regulation of 
gene expression by suppressing newly synthetised proteins through inhibition or 
destabilisation of mRNA (messengerRNA) in eukaryotes (Mashima, 2015).  
1.2.1 Discovery 
The first miRNA was discovered in 1993 by Ambros‘s and Ruvkun‘s groups in 
Caenorhabditis elegans, specifically lin-4, which is crucial in the larval development of C. 
elegans (Almeida et al., 2011). In 2000 was discovered second miRNA and there began 
outbreak of discoveries connected to miRNAs. Such as importance of DICER protein in 
miRNA pathway (Grishok et al., 2001; Hutvágner et al., 2001), connection between 
overexpression of miRNAs and cancer. Using anti-miR for therapy. Overexpression of a 
single miR is sufficient to cause cancer (O’Donnell et al., 2005). 
Silencing of the target gene is based on Watson-Crick base pairing of the miRNA with 3’UTR 
of the gene. 
1.2.2 Biogenesis of miRNAs 
Most mammalian miRNAs are transcribed in the genome at first in the form of long 
primary transcripts (pri-miRNAs) by RNA polymerase II. The pri-miRNAs consist of cap 
structure at the 5' end, one or more hairpin structures and polyadenylated 3' end. Pri-miRNAs 
can be spliced in more ways, which leads to generating more than one functional miRNA 
(Carthew and Sontheimer, 2009). In the nucleus, the pri-miRNAs are processed by RNAse II 
endonuclease III Drosha enzyme and DGCR8/Pasha protein, a double-stranded RNA-binding 
domain protein. After the excision precursor-miRNA (pre-miRNA) is formed and exported 
from the nucleus by Exportin 5 protein. After the displacement of pre-miRNA into the 
cytoplasm, pre-miRNA is cleaved by Dicer protein (Carthew & Sontheimer, 2009). The pre-
miRNA in duplex form binds to a protein of the Argonaute (Ago) family to build an RNA 
Induced Silencing Complex (RISC). Regulation of miRNA biogenesis has not been 




Fig. 2 Biogenesis of miRNA. Canonical processing pathway of miRNAs starts in nucleus, firstly there is 
primary miRNA (pri-miRNA), after cleavage by Drosha-DGCR8 complex pre-miRNA is formed and later 
exported to cytoplasm and cleaved further until the mature miRNA is formed. (Figure adapted from (Winter et 
al., 2009)  
 
1.2.3 Mechanism of function 
Further is described the mechanism of miRNA function only in animals, not plants 
(there is a different mechanism of miRNAs action). Binding of miRNA in RISC (miRISC) is 
important for specific recognition of target mRNA. Generally, miRNA-binding sites are set in 
3’UTR (untranslated region) of mRNA in multiple copies. MiRNA is bound to these sites by 
Watson-Crick base pairing in length of 2-8 nucleotides – which is called as seed region. 
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According to the level of miRNA-mRNA complementarity the way of suppressing the gene is 
chosen – perfect complementarity allows cleavage of the mRNA strand. If central mismatches 
occur, cleavage does not happen, but the translation of mRNA is repressed. Guo et al. found 
out, that inhibition of translation had just slight effect compared to destabilization of mRNA 
(H. Guo et al., 2010). It is unclear if the repression occurs in initiation of translation or in the 
later phase. There are three models of possible repression by miRISC, the first is competition 
of miRISC and eIF4E for binding to 5’ cap structure. The second is deadenylation, therefore 
destabilizing the mRNA, and the third is miRISC blocks the association of large and small 
ribosomal subunits (Chendrimada et al., 2007). MiRNAs can also act as transcription 
activators by binding to enhancer sequences (Xiao et al., 2016). 
 
1.2.4 MiR-155 expression in hematopoetic cells  
The sequence coding mature miR-155 is highly conserved in humans, mice and chickens 
(Mashima, 2015), MiR-155 physiologically involves in the lymphoid and myeloid cells 
development where the levels of miR-155 differ depending on the cell type (Georgantas et al., 
2007). During the erythroid differentiation in vitro, there was proven, that the level of miR-
155 was 200 fold lower in mature red cells, and miR-451 was upregulated at the same time. 
Demonstrating, that these two miRNAs are crucial for differentiation in myelopoiesis and 
erythropoiesis (Georgantas et al., 2007).  
One of the roles of miR-155 is maturation of B-cell and T-cell. MiR-155 is known as 
oncomir to many types of leukemias/cancers, such as Hodgkin Lymphoma and subtypes of 
Non-Hodgin lymphomas (Eis et al., 2005; Kluiver et al., 2005). MiR-155 is also involved in 
inflammatory pathways. The B-cell development is directly affected by transcriptional 
factors, which are connected to miRNAs. Deregulated expression of miRNAs and 
transcription factors are key events in pathogenesis of B-cell malignancies(Fabbri & Croce, 
2011). In physiological lymphopoiesis, the highest level of miR-155 is expressed in germinal 
center cells, intermidiate level hematopoietic stem cells and the lowest mature B-cells 
(Georgantas et al., 2007). It has been reported that direct target of miR-155 is SHIP1 (Src 
homology-2 domain-containing inositol 5-phosphatase 1) gene that regulates differentiation of 





Mouse models of miR-155  
Until now it was generated four main miR-155 transgenic mouse models with either 
enhanced (Costinean et al., 2006) or deficient miR-155 expression (Thai et al., 2007; Vigorito et 
al., 2007). More information about mechanism of miR-155 acting in immune system may help 
to understand its role in leukemic process. 
In the miR-155 over-expressing transgenic mice ("Eμ–mmu-miR-155" mouse model), pre-
leukemic stage with polyclonal B-cell expansion and splenomegaly developed initially (after 
3 weeks). Later, after seven month, pre-leukemic stage progressed into high-grade B-cell 
lymphoma that is direct evidence of miR-155 functioning as activator of leukemia 
development(Costinean et al., 2006)  
Vigorito et al., confirmed importance of miR-155 in antibody production in germinal centers 
(Vigorito et al., 2007). MiR-155 deficient mice had reduced proportion (50%) of germinal 
center B-cells that led to reduced production of high affinity antibodies. Interestingly, authors 
firstly thought that impaired antibody production is result of dysfunctioning of somatic 
hypermutation affected by miR-155. The further experiments showed that miR-155 does not 
affect somatic hypermutation that occurs in germinal center B-cells (Vigorito et al., 2007). 
Failure of antibody production is due to block in differentiation of plasmablast B-cells (stage 
of B-cells between plasma and mature B-cells) and in reduced production of cytokines. This 
was confirmed also by other groups of researchers as Thai and Rodriguez(Rodriguez et al., 
2007; Thai et al., 2007). Moreover, the miR-155 deficient mice produced less amount of IgM 
and switched antigen specific antibodies after immunization with pathogen – Salmonella 
typhinurium. The evidence that miR-155 regulates also T-cells represents its strong up 
regulation in activated T-cells (Thai et al., 2007). Rodriguez et al., also proved that dendritic 
cells failed efficiently activate T-cells (Rodriguez et al., 2007). 
As the miR-155 bears the potential to be therapy-targeted molecule, Babar et al., 
generated miR-155 Cre-loxP tetracycline controlled knock-in mouse model (miR-155LSLtTA). 
In these mice, the transcription of miR-155 can be deactivated by doxycycline, thus it 
provides “TET OFF” system with temporal controlling of miR-155 transcription. MiR-155 
LSLtTA mice developed after five month disseminated lymphoma with enlarged lymph nodes 
and splenomegaly. Surprisingly, mice with such miR-155 induced lymphoma after 
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doxycycline treated food displayed within two days reduced lymph nodes and in 2 weeks the 
lymphoid organs were as in normal, healthy mice (Babar et al., 2012).  
To summarize, over expression of miR-155 leads to high grade B -cell lymphoma and 
miR-155 knockout mice model showed on a marked impairment of miR-155 in T- and B-cell 
function. The knock-in mouse model gave strong evidence that miR-155 is inductor of B-cell 
leukemia. Moreover, miR-155 regulates homeostasis of immune system, thus it makes 
potentially very powerful therapy tool.   
 
Regulatory role of miR-155 and its targets 
The number of target genes according to miRTarBase is 3287 (January, 2021), which 
supports the fact that miR-155 represents multifunctional miRNA. Some of miR-155 target 
genes are shown in figure 3, showing, that miR-155 is not extended just by number of target 
genes, but also by the location of function of target genes. 
 
Fig. 3  Schematic view of miR-155 targets. Target genes modulated by miR-155 in malignant 
development and progression are included in group of transcription factors located in nucleus (e.g. 
PU.1), kinases in cytoplasm (e.g. MAP3K7), binding proteins (e.g. SATB1), membrane bound 
proteases (e.g. INPP5D), and proteases, kinases and enzymes in cytoplasm. (Adapted from 




The group of Yu et al.found out, that just in colorectal carcinome, the miR-155 is responsible 
for regulating the proliferation, cell cycle, apoptosis and migration of colon cancer cells (Yu 
et al., 2017). The inhibition of apoptosis by affecting by PTEN pathway was confirmed in 
psoriasis by (Xu et al., 2017). Knockout of miR-155 in mice lead to attenuation of immune 
system (Vigorito et al., 2013). 
Out of these miR-155 targets, only a few are related to B cell development, cell cycle, 
differentiation, and CLL pathogenesis. Certain targets (such as PU.1 and proto-oncogene 
MYB transcription factors) belong to the group of so-called "master regulators" of gene 
expression in hematopoiesis. PU.1 controls the process of hematopoietic cells differentiation 
in a dose-dependent manner (DeKoter & Singh, 2000). In a case of B cell differentiation, a 
low level of PU.1 restrains B cell production. At a higher level, PU.1 blocks the 
differentiation of B cells into plasma cells (Lu et al., 2014; Vigorito et al., 2013). Previously 
group of Vargova et al. described the direct negative relationship between the elevated level 
of miR-155 and downregulation of PU.1 in CLL(Huskova et al., 2015; Pospisil et al., 2011; 
Vargova et al., 2017) (Vargova et al. 2011, Huskova et al. 2015, Vargova et al, 2017). A 
recent study shows that miR-155 affects mitosis and chromosomal stability during 
tumorigenesis. The authors described novel targets of miR-155 that interact with cell cycle 
regulatory proteins. The mechanism of miRNA action on genome stability and ploidy is still 
described scarcely.  
The question of how miRNAs orchestrate the cell fate through their respective targets in CLL 
remains enigmatic. Answering this question is crucial for the understanding of the molecular 
network of CLL leukemogenesis. 
Genome editing technology using clustered regularly interspaced short palindromic repeats 
(CRISPR/Cas9) becomes today's routine method for fast and precise editing of any gene of 
interest. Successful usage of this novel technology in large-scale in practically all research 
fields was described .Until now, there are only a few research papers describing the usage of 





1.3  Gene editing technology – CRISPR 
 
Abbreviation CRISPR means Clustered Regularly Interspaced Short Palindromic Repeats. 
Presence of these repeats is used as a defense mechanism against viruses in bacteria and 
archaea. Originally CRISPR was described by Yoshizumi Ishino in 1987, who discovered it 
accidentally.  At that time the function of CRISPR was unknown.  
In 2000 Mojica identified interrupted direct repeats in other species of bacteria and proposed 
the acronym CRISPR that is used until now. 
With abovementioned palindromic repeats in CRISPR system are tightly associated proteins, 
which are called Cas – CRISPR Associated Protein (Cas). There are two classes I and II that 
subdivides into types. Formerly only four types were known. Recently there are described six 
types (Makarova & Koonin, 2015; Mohanraju et al., 2016). The most known and applied in 
research is Cas9 type which is also used in this thesis. Cas proteins have helicase and nuclease 
activity which is used during the excision of targeted DNA. 
1.3.1  Introduction to CRISPR technology - history 
In 2005 three independent research groups figured out that CRISPR spacers have the 
origin in viral DNA, based on the presence of sequences root from previous infections (Grissa 
et al., 2007; Horvath & Barrangou, 2010; Marraffini & Sontheimer, 2010). This prompted 
them to the idea that CRISPR could be a part of adaptive immunity in bacteria. 
In 2007 was experimentally proven that CRISPR is a part of the adaptive immunity system, 
when they transferred resistance to a different clone of Streptococcus thermophilus by 
deleting and adding spacers (R. Barrangou et al., 2007; Hille et al., 2018; Lander, 2016; 
Morange, 2015). 
Emmanuelle Charpentier and Jennifer Doudna received in 2020 Nobel Prize in Chemistry 
for adapting CRISPR/Cas9 system and using it for genome editing. They changed the four-
component Cas9 endonuclease into two-component, which is easier to handle. This artificial 
system has the ability programmed bind to any target DNA sequence and cut at a specific 
place (Garneau et al., 2010). Also group of Virignijus Šikšnys reprogrammed the target site, 
so it was possible to bind target DNA, by changing the sequence of crRNA- crispr RNA. 
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In 2013 CRISPR was successfully used on mammalian cells. First one who described genome 
editing by CRISPR/Cas9 was group of Feng Zhang and George Church, who edited human 
cell culture (R. Barrangou et al., 2007; Rodolphe Barrangou, 2015; Deltcheva et al., 2011) . 
CRISPR editing technique was then widely spreaded in another species of mammals, such as 
mice, monkeys and human embryos (X. Guo & Li, 2015; H. Wang et al., 2013). 
3.2 Mechanism of CRISPR function in Mammalia 
 
Fig. 4 CRISPR/Cas9 system of function (Mojica & Montoliu, 2016) Not drawn to scale. In (A) is 
presented the naturally occurring Type II CRISPR-Cas system in Streptococcus pyogenes and the mechanism of 
defense against viruses. (B) The crucial parts were taken and assembled in a few or one plasmid cassette. These 
are then used in mammalian cells or embryos. (C) CRISPR-Cas9 system develops double-strand break in the 
target DNA. In order to repair this break, cells perform two endogenous mechanisms of fixing, NHEJ – Non-
Homologous End Joining, which is connected to deletion or insertion of nucleotides, leading to gene disruption. 
The second option is HDR- homology-directed repair, which requires a matrix in order to be copied (Mojica & 
Montoliu, 2016). There are different ways how to insert these particles or plasmids into cells, such as 




1.3.2 Editing of miRNAs by CRISPR 
 
Fig. 5 (Emerging Role of CRISPR/Cas9 Technology for MicroRNAs Editing in Cancer Research | Cancer 
Research, b.r.) 
Using CRISPR/Cas system in gene editing is highly appreciated because of its easy 
design, high targeting efficiency and almost none off-target mutations. CRISPR/Cas9 system 
is versatile and used among many species for its high-throughput and multiplexed gene-
editing approaches (Friedland et al., 2013; Kistler et al., 2015). Cas9 protein binds to DNA by 
specific pairing of sgRNA bound to the target DNA sequence. CRISPR/Cas9 
system performs double strand break of the target DNA three base pairs upstrem to PAM 
sequence (shown in Fig. 5). During gene-editing, there is used the selfability of the cell to 
repair the double DNA break by its endogenous repair machinery, this gene-editing technique 
is used also in in vivo and in vitro, in order to investigate more human diseases (Chang et al., 
2016; SHAO et al., 2016). 
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As was mentioned before in part 2.4.2 „Regulatory role of miR-155 and its targets“ in 
miRNA expression could lead into cancer. Gene editing by CRISPR is also used for 
curing different types of cancer by modulating the miRNA expression. Successful gene 
editing of specific miRNA sequences resulted in changes of its targets - mainly oncogenes, 
was performed on cells from renal cell carcinoma, pancreatic cancer and 
chronic myeloid leukemia (He et al., 2014; Y. Wang et al., 2012; Yoshino et al., 2017).  
Using CRISPR as therapeutic tool concerns non-target loss of function by deleting miRNAs, 
which are cancer/leukemia specific. To avoid this concerns, there is possibility to use tissue-
specific promoters. Another possibility is to use modified Cas9  - edited in its nuclease 
activity to perform only nicks in one strand instead of double strande break. Decreasing the 
size of sgRNA lowers off-target binding (Fu et al., 2014).  
On the other hand, targeting only miRNA sequences may not be sufficient for therapeutic 
purposes. Because in some diseases, specially cancer, there is malfunction of pathways 
including few genes, not just one. Previously, Kabadi and colleagues (Kabadi et al., 2014) 
used a Cas9 in plasmid with four different sgRNAs and successfully sustained transcriptional 
activation. The way of delivering the plasmid may still cause some difficulties especially in 
















Imbalance in miRNA expression represents one among many factors 
that initiate leukemia/cancer.  OncomiR-155 is highly expressed in many leukemias/cancers, 
including CLL. The process of leukemogenesis is associated with changes in the gene 
expression profile of mRNAs, the miRNAs targets. Elevated levels of miR-155 results in 
suppression of its targets. 
We hypothesize that by gene editing of CLL B - cells we unblock miR-155 targets and find 
out correlation between these targets (known and also unknown) in CLL during leukemia 
progression. 
2.1 Aims of the thesis 
1.  By CRISPR/Cas9 tool create deletion mutant of human B-CLL cell line HG-3 that does 
not express miR-155. 
2. Explore the impact of miR-155 deletion on HG-3 cell line viability and proliferation. 
3. Perform qRT-PCR to compare the gene expression profile of HG-3 cells before and after 
gene editing. 
  
2.2 Specific aims of the thesis 
1. What kind of differences we can detect in the transcriptom of CLL cell line HG-3 and 
MEC-1 after deletion of miR-155 by CRISPR/Cas9 in these cells? (up/down expression of 
miR-155 targets; validated/novel) 
2. Show HG-3 and MEC-1 similar trend in the proliferation rate before and after miR-155 





3. Material and Methods 
In all experiments performed in this thesis, the HG-3 and MEC-1 cell lines were used. 
HG-3 cell line is derived from a Caucasian man diagnosed with an early stage of Chronic 
Lymphocytic Leukemia disease. MEC-1Experiments with MEC-1 cell line were performed 
earlier by Dr. Savvulidi Vargová. Both cell lines were treated with nucleofection and insertion 
of plasmid, which consisted of  Cas9 (CRISPR associated protein 9), gRNA (guide), GFP 


























Fig. 6 Plasmid used for CRISPR/Cas9 gene editing - U6gRNA-Cas9-2A-GFP MiR155. 
Afterwards the viable cells that contained GFP were selected by Fluorescence-
activated cell sorting. Clones of GFP positive HG-3 cells were cultivated for 3-4 weeks after 
nucleofection. After that, cryopreservation, DNA and RNA isolation were performed.  
Isolated DNA was multiplied by Polymerase Chain Reaction (PCR), then transferred to 2% 
Agarose electrophoresis gel. The PCR product of the desired length was isolated from the gel 
and sequenced (Sanger sequencing) to verify if desired deletion of 22 nt responsible for 




Isolated RNA of gained clones with deletion of sequence for  mature miR-155 was used for 
Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR). This PCR 
product – complementary DNA (cDNA) was utilized for measuring the changes in 
transcriptome. The transcriptome of clones was measured and verified by qPCR. 
3.1 Material 
3.1.1 Biological material 
HG-3 Cell line 
HG-3 cell line is derived from a 70year old Caucasian man diagnosed with an early stage of 
Chronic Lymphocytic Leukemia disease (Rai stage II). HG-3 cell line was obtained from 
DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen – German Collection of 
Microorganisms and Cell Cultures). Morphology of HG-3 cells is described as round 
suspension cells partly growing in clumps and slightly adherent. Its doubling time is between 
50 and 60 hours. The imunology profile is negative in these clusters of differentiation: CD3, 
CD4, CD10, CD13, CD34; positive in these: CD5, CD15, CD19, CD20, CD37, CD80; 
HLA−, DR+, cyIgG−, cyIgM+, cyκ−, cyλ+.  
The karyotype is near-diploid: 46(44-46)<2n>XY, der(10)t(10;11)(q26;q24.1), 
del(13)(q12q32), there is marginal resemblance to original karyotype. The karyotype consists 
of 44-46 chromosomes including XY chromosomes, derivative chromosome 10 consisting of 
q26 part of 10th chromosome and q24.1 part of 11th chromosome; deletion of the13th 
chromosome is present between q12 and q32 part of the chromosome. 
MEC-1 cell line 
MEC-1 cell line was established in 1993 from the peripheral blood of a 61-year-old Caucasian 
man with chronic B cell leukemia (B-CLL in prolymphocytoid transformation to B-PLL. HG-
3 cell line was obtained from DSMZ (Deutsche Sammlung von Mikroorganismen und 
Zellkulturen – German Collection of Microorganisms and Cell Cultures). Morphology of 
MEC- 1 cells is described as round to polymorphic cells growing in suspension, singly or 
partly in small aggregates, a few cells are slightly adherent. . Its doubling time is around 40 
hours. The imunology profile is as follows: CD3 -, CD10 -, CD13 -, CD19 +, CD20 +, CD34 
-, CD37 +, CD38 +, cyCD79a +, CD80 +, CD138 +, HLA-DR +. 
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The karyotype is near-diploid with 10% polyploidy - 46(44-47)<2n>XY, -2, +7, -12, +1-
2mar, t(1;6)(q22-23;p21), add(7)(q11), der(10)(10pter->q22::?::2q11->qter), del(17)(p11) - 
small acf/mar present in most cells - resembles published karyotype. 
3.1.2 Chemicals and buffers 
 
Dimethylsulfoxid(DMSO)     Sigma-Aldrich  
Fetal Bovine Serum (FBS)    Biosera  
Isopropylalkohol p.a.     Sigma-Aldrich  
Penicilin-Streptomycin (100x)  Sigma-Aldrich 
Phosphate Buffered Saline (PBS) (10x)   Biosera 
Propidium iodid (PI)   Sigma-Aldrich 
RPMI 1640 medium  Biosera  
TRI reagent    iBioTech  
plasmid U6gRNA-Cas9-2A-GFP MiR155    Sigma-Aldrich 







Amaxa™ Human B Cell Nucleofector™ Kit   Lonza  
DNeasy Blood & Tissue kit     Qiagen  
QIAEX II® Gel Extraction Kit    Qiagen  
TaqMan Universal PCR Master Mix    Thermo Fisher Scientific 
 
Plasmids 
Plasmid which was used for CRISPR/Cas9 reaction is U6gRNA-Cas9-2A-GFP MiR155. The 
original amount was inserted in E.coli and isolated in higher amount later. 
3.1.3 Instruments 
Amaxa nucleofector Device II    Lonza  
BD FACS Aria IIu cell sorter    BD Biosciences  
BD FACS Canto II fluorescence analyser   BD Biosciences  
Bioanalyzer 2100      Agilent Technologies  
iBlot Gel Transfer System     Life Technologies  
Mastercycler Gradient     Eppendorf  
7900HT Fast Real-time PCR System   Life Technologies 




3.2.1 Cultivation of HG-3 cell line 
HG-3 cell line was cultivated in medium made out of  RPMI, 10 % of FBS and 1 % of 
antibiotics – penicilin/streptomycin. The temperature was 37°C and concentration of CO2 5%. 
Concentration of the cells was between 0,5-1 million cells per mililiter. Culture medium was 
changed every 2 - 3 days. 
Transfection of HG-3 Cells by Amaxa nucleofector 
Procedure/method 
One day prior nucleofection 
1. Firstly the cell number was determined. For one nucleofection reaction 2x106 cells was 
used. 
2. Cells were cultured in RPMI medium supplemented with 10 % of FBS, without P/S, 
24 hours prior nucleofection. For each well 2 ml of this complete medium was used. 
3. Cells were cultured in humidified incubator with 5 % CO2 and 37°C. 
Day of nucleofection 
1. Plasmids which were used: 
a.  GFP (pMAX GFP, Amaxa nucleofection kit) c = 0,5 µg/µl as positive control; 
2 µg per reaction  
b. CRISPR/Cas9/miR-155 c = 1 µg per reaction  
c. CRISPR/Cas9/miR-155 c = 2 µg per reaction  
2. Nucleofection solution was prepared. For each reaction 100 µl of complete 
nucleofection solution was used. Complete nucleofection solution was mixed in ratio 
of solution:supplement 4,5:1. Nucleofection solution was kept in room temperature in 
laminar hood. 
3. Prepared RPMI medium (without P/S) was preheated at 37°C and divided in 6 well 
plate; 2 ml of medium per well. 
4. Cells were spinned down in eppendorf tubes for 5 minutes, in room temperature with 
velocity 1900 rpm (300 rcf). Supernatant was discarded and the cell pellets were kept 
on ice. 
5. For nucleofection of HG-3 cells by Amaxa nucleofector, nucleofection kit #VPA-1001 
and program U-015 were used. 
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3.2.2 FACS – Fluorescence Activated Cell Sorting and Gaining of the Clones 
24 hours after nucleofection desired cells were sorted out by flow cytometry (FACS 
ARIA II, BD FACSDiva 8.0.1). By sterile single-cell sorting only GFP positive (wavelength 
510 nm) and propidium iodid negative (wavelenght 617 nm) cells were sorted out in 96 well 
plate (Fig. 7).  
 
Fig. 7 Presentation of perfomed FACS sorting. 
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Sorted single-cells were cultivated in RPMI medium supplemented with 10 % FBS 
and 1% P/S in humidified incubator with 5 % CO2. The single cell clones were harvested 
(after 3-4 weeks of culturing) when the cells reached density around 500 000 cells per 
mililiter to perform DNA and RNA isolation. 
 
3.2.3 Sequencing  
Sanger sequencing was performed in BIOCEV facility. 
 
DNA Isolation 
DNeasy Blood & Tissue Qiagen kit for DNA isolation was used and followed the 
manufacturer`s protocol: Purification of Total DNA from Animal Blood or Cells (Spin-
Column Protocol) with some modifications. 
Protocol for cultured cells was followed and the amount of 5x106 cells was used. Firstly the 
cells were cleaned by centrifugation at speed 14 000 rpm (20 817 G) in PBS for 5 minutes at 
room temperature. The supernatant was discarded. Then the instructions were followed. 
Ethanol (96 %) was used. At step 7 in protocol 100 µl of nuclease-free water (preheated at 
56°C)  instead of Buffer AE was added into the spin column. This eppendorf tube with spin 
column was left for 5 minutes at room temperature, spinned down for 1 minute at 8 000 rpm 
(6797 G), at room temperature. Concentration of DNA was measured by Nanodrop 
spectrophotometer. The gained DNA was stored at 4°C for short term and at -20°C for long 
term.  
PCR reaction – preparation of product for Sanger Sequencing 
Isolated DNA from the previous step was multiplied by Polymerase chain reaction. 
Because this PCR product was later needed for sequencing, AccuTaq™ LA DNA Polymerase 
was used. The protocol below for the PCR was pursued. The quantity of gDNA was 100 ng, 
which differed in the volume of µl, according to the concentration of DNA in the isolated 
solution. Altogether the amount for H2O and DNA solution was 11.8 µl. For gaining aspecific 





The sequences of primers were following: 
Primers Sequence Tm 
Forward primer CTCCAGCTTTATAACCGCATCTGC 58°C 
Reverse primer GTTGAACATCCCAGTGACCA 50°C 
 
Whole reaction mixture consisted of following components: 
Reaction:                                                                                                                          1x 
 
 
Program of the reaction was following: 
Program:   98°C 30 sec  
   94°C 10 sec  
   60°C 20 sec 35 cycles 
   68°C 1 min  
   60°C 10 min  
   4°C 1 min  
   4°C hold  
 
Gel electrophoresis 
For gel electrophoresis 2 % agarose gel was used. Gel was prepared with TBE solution 
and 2.5 µl of ethidium bromide was added per 50 ml of gel. Loading dye was diluted 6 times 
in PCR product and this mixture was loaded on agarose gel (20 µL/lane). Electrophoresis 
lasted one and half hour, with 80 V. For detection of PCR product size DNA ladder 100 bp 
was used.  
     
Accutaq LA 10x buffer 
 
2.0 
dNTPs (2.5 mM each, final 10mM) 4.0 
DMSO (final c=2%) 
  
0.4 
primer F+R 10uM PCR/Seq 
 
1.6 




   
10.8 
gDNA (100 ng/µl)       1.0  
Total 




Detection of PCR product 
Runned agarose gel was viewed by ChemiDoc™ Imaging System to check the size of 
PCR product. Desired band with proper size of PCR product was cutted out from gel under 
UV light. Afterward DNA was isolated by gel extracation kit. 
DNA extraction from gel 
For DNA extraction of desired length from gel commercial QIAEX II® Gel Extraction 
kit was used. The manufacturer`s protocol only with small modification was carefully 
followed. Modification was done in 9th step where instead of TE buffer the preheated at 56°C 
nuclease-free water was used. 
Gene expression 
RNA Isolation 
Before starting the RNA Isolation all of the surface and pipettes were cleaned by 
Nuclease Eliminator solution. 
 1) Cells were harvested, until the amount of 5x106 cells was reached. This amount was 
centrifuged for 5 minutes at room temperature. 
2) Pellet was resuspended in TRI reagent and left for 5 minutes to complete cell lysis, on 
bench at room temperature. 
3) To the TRI reagent cell suspension 100 µl of chloroform (CHCl3) was added. This was 
mixed by vortexing for 2 seconds and left for another 5 min on the bench. After this, the 
mixture was centrifuged at 11000 rpm (13552 rcf) for 15 min at 10°C. 
4) The clear upper phase (~250 µl) was transfered into a new eppendorf tube and mixed with 
the same amount of CHCl3, vortexed and centrifuged at 11000 rpm for 7 min at 10°C. 
5) The clear upper phase was transfered into new eppendorf tube and 1 µl of linear acrylamid, 
250 µl of Isopropanol was added. This was vortexed, shortly spinned and precipitated at −20 
°C overnight. 
6) The other day the tube was shortly vortexed and centrifuged at 14000 rpm for 30 min at 4 
°C. 
7) The supernatant was decanted, to the pelet 500 µl of 75 % ethanol was added, vortexed 
gently and centrifuged at 14000 rpm for 5 min at 4 °C. 
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8) Supernatant was again decanted, mixture was spinned down shortly and removed rest of 
the liquid completely, left the pellet to dry on the air for 3-5 min covered with a paper towel. 
9) The RNA pellet was in 12 µl of nuclease free water with RNAse inhibitors (1 %) dissolved 
and analyzed by Nanodrop. 
The RNA was stored at −80°C. 
 
cDNA synthesis (RT-PCR – reverse transcriptase polymerase chain reaction) 
For cDNA synthesis RT Kit was used with reaction mixture below: 
Reaction: 
 
   
 
1x (µl)  
10x RT buffer    
 
1.50  
25x dNTPs (100 mM)  0.15  
RNAse Inhibitors 
 
   
 
0.10  
RT Random primers    
 
0.25  
5x primer miR    
 
1.50  
H2O (nuclease-free)    
 
6.50  
Reverse transcriptase (RT)     1.00  
RNA (100 ng/µl)      1.00  
total       15.0  
         
 
Program for reaction was following: 
Program:   16°C 30 min  
   42°C 30 min  
   85°C 5 min  
 
After run of whole program 35 µl of nuclease-free water was added to reach the final amount 
of 50 µl. 
 
qPCR – quantitative polymerase chain reaction 
Mixture for qPCR reaction consisted of 2 fractions – DNA Master Mix and Primer 
Master Mix. Final volume of PCR reaction was 8 µl in total. 
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DNA Master Mix:       1x (µl) 
TaqMan (Universal PCR Master Mix, cat. nr. 4324018)  2.0 
H2O (nuclease-free)    1.5 
cDNA        0.5 
total        4.0 
         
         
Primer Master Mix:     1x (µl) 
TaqMan (Universal PCR Master Mix, cat. nr. 4324018)  2.0 
Primer (20 µM)       0.4 
Probe (10 µM)       0.1 
H2O (nuclease-free)   1.5 
total        4.0 
  
miRNA Master Mix  
 1x (µl) 
Taq    2.0 
20x miR primer   0.4 
H2O (nuclease-free)    1.6 
total     4.0 
 
There were two separate mixtures for primers, one was for coding genes with specific probes 
for each gene; the other one for miRNA genes. Firstly 4 µl of Primer Master Mix were 
pipetted in 384 well plate, after that 4 µl of DNA Master Mix.  
The reaction was performed by real time PCR instrument (HT7900, ABI) and with following 
program. 
Program   
95°C 15 s 40 cycles 











Leukemia and cancer development are highly connected to cell cycle and its pathways. 
Any slight change can have huge impact on future development of the cell (Vermeulen et al. 
2003; Ghelli Luserna di Rorà et al. 2019). Small non-coding RNAs have much bigger impact 
on changing the expression of genes, than was earlier assumed. In this thesis we focused on 
studying the impact of miR-155 on two cell lines of Chronic Lymphocytic Leukemia. 




Fig. 8 Workflow of performed experiment. 1. Firstly there was cell line nucleofected with plasmid containing 
genes for CRISPR/Cas9 editing of miR-155. 2. Nucleofection was performed by AMAXA Nucleofector. 3. 
GFP+ and PI- cells were selected for further experiments by FACS. 4. Cultivation of selected clones lasted about 
3-4 weeks, until gaining sufficient amount of cells for DNA and RNA isolation. 5. Experiments, such as PCR, 
Sanger sequencing – for confirmation of success rate in deleting of target region, qRT-PCR – for measuring the 




Here we focused on the leukemic HG-3 (shown in 9) and MEC-1 cell lines. 
 
Fig. 9 HG-3 cell line (native). It is stable CLL cell line that consists of kvazi-mature B-cells growing in 
suspension. Magnification is 200x; one cell is around 5-10 µm large. The red line in the picture represents 25 
µm. 
 
Editing of the sequence coding for mature miR-155 by gene-editing technology CRISPR/Cas9 
was performed in HG-3 cell line, which represents chronic lymphocytic leukemia (CLL) in 
early stage of progression. Editing of MEC-1 cell line was done in laboratory by others, in 
this thesis were perfomed experiments as cell count, cell viability and qRT-PCR. MEC-1 cells 
represents adverse CLL stage with TP53 deletion (del17) (p11). For each gained clone of HG-
3 cell line we performed separation of PCR product gel elektrophoresis followed by Sanger 
sequencing to check correctness of gene editing. Fig. 10 shows PCR product of single cell 









The model and effectivity of CRISPR/Cas 9 editing is shown in Fig. 11 and 12 for each cell 
line separately. Using the modern gene-editing technology CRISPR/Cas9 (Fig. 11B, C and D) 
we have successfully edited the sequence responsible for mature miR-155 at one genomic loci 
in HG-3 cells. This heterozygous clone #4 bears partially the deletion of the desired sequence, 
confirmed by Sanger sequencing of the PCR product (Fig. 11E).  The same was performed 
with MEC-1 cell line, with the difference of gaining homozygous clone with deletion at both 
strands of DNA (Fig.11). 
Fig. 10: PCR product of nucleofected HG-3 cell line with CRISPR/Cas9/miR-155 plasmid. Picture 
depicts different PCR product in CRISPR/Cas9/miR-155 clones isolated from HG-3 cell line. PCR product 
was separated on 2 % agarose gel, runned by 80 V/90 min. Size of PCR product of unedited miR-155 (ctrl) is 
358 bp. First column contains DNA ladder 100 bp (#SM0323, ThermoScientific), second column represents 
positive control - clone #48 with biallelic deletion of miR-155 in MEC-1 cell line, third column represents 
negative control – wild type of HG-3 cell line (ctrl), fourth column represents clone #3 of HG-3 cell line, fifth 
column represents clone #4 of HG-3 cell line - containing changes in DNA sequence compared to wild type, 











Fig. 11: Schematic illustration of MIR155HG, CRISPR/Cas9 miR-155 vector, and deletion of miR-155 
in HG-3 cells. (A) Structure of the MIR155HG/BIC gene (NC_000021.8). MIR155HG (BIC) is localized on 
the 21q21.2 chromosomal locus. The full length of MIR155HG spans 13 024 bp that contains three exons. 
The exon 3 encodes precursor pre-miR-155 (1421 bp). After two endonuclease cleavage steps (by 
endonuclease Drosha and Dicer) arises the mature miR-155 (adapted and modified from Tam W, 
2001,http://www.ncbi.nlm.nih.gov/gene/114614). (B) Scheme of MIR155HG/BIC gene with depicted and 
highlighted sequence for mature miR-155 (23 bp).  (C ) The sequence of MIR155HG coding mature miR-155 
(in bold) and target sequence for gRNA. The PAM sequence AGG in red color. (D) Scheme of 
CRISPR/Cas9/miR-155 vector (pU6gRNA-Cas9-GFP, 8274 bp, Sigma). The vector contains Kanamycin 
resistance, the sequence for green fluorescence protein (GFP) used as a selection mark. (E) The 
scheme shows the region of MIR155HG from 5` 11819 to 11879 3` end, where 21 nt are deleted in case of 
HG-3 miR-155 deficient clone #4 (heterozygous mutation) in comparison to ctrl (non-edited HG-3 cells). 
Seed sequence is TAATGCTA. The lower part of the picture shows chromatograms (Sanger sequencing, 
































 11812                                                                                                                     11867
gDNA MIR155HG  3`... CTGTATGCTG TTT...5`
CRISPR gRNA         3`..........CTGTATGCTG  TTT...5`
                                   miR-155
TTAATGCTAATCGTGATAGGGG 
TTAATGCTAATCGTGATAGGGG



























Fig. 12: Schematic illustration of MIR155HG, CRISPR/Cas9 miR-155 vector, and deletion of miR-155 in 
MEC-1 cells. (A) Structure of the MIR155HG/BIC gene (NC_000021.8). MIR155HG (BIC) is localized on the 
21q21.2 chromosomal locus. The full length of MIR155HG spans 13 024 bp that contains three exons. The 
exon 3 encodes precursor pre-miR-155 (1421 bp). After two endonuclease cleavage steps (by endonuclease 
Drosha and Dicer) arises the mature miR-155 (adapted and modified from Tam W, 
2001,http://www.ncbi.nlm.nih.gov/gene/114614). (B) Scheme of MIR155HG/BIC gene with depicted and 
highlighted sequence for mature miR-155 (23 bp).  (C ) The sequence of MIR155HG coding mature miR-155 
(in bold) and target sequence for gRNA. The PAM sequence AGG in red color. (D) Scheme of 
CRISPR/Cas9/miR-155 vector (pU6gRNA-Cas9-GFP, 8274 bp, Sigma). The vector contains Kanamycin 
resistance, the sequence for green fluorescence protein (GFP) used as a selection mark. (E) The scheme shows 
the region of MIR155HG from 5‘ 11819 to 11879 3‘ end, where 21 nt are deleted in case of MEC-1 miR-155 
deficient clone #48 (homozygous mutation) in comparison to ctrl (non-edited MEC-1 cells). Seed sequence is 
TAATGCTA. The lower part of the picture shows chromatograms (Sanger sequencing, Chromas software for 









Fig. 13: Gene expression profile of miR-155 targets (validated, novel bona fide CLL related) in HG-3 
and MEC-1 cell lines. Graph on the upper part of the figure shows data from HG-3 cell line, knock-out in 
one DNA strand hsa-miR-155 gene. Graph on the bottom shows data from MEC-1, knock-out on both DNA 
strands of hsa-miR-155 gene. Ct values of experimental genes were normalized to the reference gene 
GAPDH. The expression of mRNAs was determined by TaqMan chemistry. A Confirmed (based on 
miRtarBase database) miR-155 targets are in left part of the graph, B Novel, and bona fide CLL related miR-
155 targets are behind the red line. Data are from 2 independent experiments. Ctrl (gene expression of cells 






Fig. 13 depicts results of qPCR measurement. In part, which is labeled “A” in first 
column is wild type (unedited cell line) of each cell line set at 1 as a control, the expression of 
other genes is normalized to this value. Following genes (selection of genes was done based 
on mRNAseq data of MEC-1 cell line) are validated targets of miR-155: GNB4 - G Protein 
Subunit Beta 4 gene is located in plasma membrane, coding G protein subunit. SRSF1 - Serine 
And Arginine Rich Splicing Factor 1 protein is located in nucleus and is part of alternative 
splicing.  
PU.1- Transcription factor PU.1, located in nucleus which binds to a purine-rich DNA 
sequence, can act as lymphoid-specific enhancer, this protein is specifically involved in 
activation and differentiation of macrophages and B-cells. HMGCS1-Hydroxymethylglutaryl-
CoA synthase is an enzyme, located in cytosol and nucleus, catalysing condensation of acetyl-
CoA with acetoacetyl-CoA. NSNU5 - NOP2/Sun RNA Methyltransferase 5 codes a protein 
located in nucleus, member of conserved family of methyltransferases. PDCD4 – coding gene 
of Programmed Cell Death 4, which is located in nucleus and cytosol, works as tumor 
suppressor. PRKAR1A - Protein Kinase cAMP-Dependent Type I Regulatory Subunit Alpha, 
located in plasma membrane and cytosol.  
CDKN1A - Cyclin Dependent Kinase Inhibitor 1A is in nucleus and cytosol. This gene 
encodes a potent cyclin-dependent kinase inhibitor. This specific inhibitor binds to cyclin-
cyclin-dependent kinase 2 or 4 complexes, therefore works as regulator of cell cycle in G1 
phase. Expression of this gene is regulated by p53, suppressor protein and can stop the 
proliferation of cell. In part “B” of the Figure 13 are genes, which are potential targets of 
miR-155 associated with CLL. HIST1H2AC - Histone H2A type 1-C, this protein is located 
solely in nucleus, part of nucleosomal octamer.  
LDHA - Lactate Dehydrogenase A is located in extracellular compartment, cytosol 
and nucleus. This protein catalyzes the metabolic pathway – converting of L-lactate and NAD 
to pyruvate and NADH, as last step of anaerobic glycolysis. This protein is more expressed in 
cancer and leukemic diseases in order to avoid using mitochondria and cellular respiration 
cycle as source of energy. THRAP 3 - Thyroid Hormone Receptor Associated Protein 3, 




RRP15 - Ribosomal RNA Processing 15 Homolog, located in nucleus, part of protein 
maturation processes. PSMG2 - Proteasome Assembly Chaperone 2, located in nucleus, 
plasma, membrane and cytoskeleton, one of chaperone proteins, part of assembly of 20S 
proteasome.  
PNN - Pinin, Desmosome Associated Protein, located in nucleus, plasma membrane 
and cytoskeleton, transcriptional activator of the E-cadherin promoter gene. RPS29 – 
Ribosomal Protein S29, located in cytosol, extracellular compartment, nucleus, endoplasmic 
reticulum, this protein is component of the 40S subunit of ribosomal proteins. VIM – 
Vimentin, located in extracellular compartment, cytoskeleton, peroxisome and cytosol, part of 
intermediate filament protein.  
TMSB4X - Thymosin Beta 4 X-Linked, located in cytoskeleton, nucleus and cytosol, 
actin sequestering protein, plays a role in actin polymerization, this protein is also involved in 
cell proliferation, migration and differentiation.  
MX1 - MX Dynamin Like GTPase 1, located in nucleus and cytosol, this gene encodes 
protein, which participated in the cellular antiviral response. ISG15 - ISG15 Ubiquitin Like 
Modifier, located in extracelular compartment, nucleus and cytosol, this protein functions 
similarly as ubiquitin.  
LMNA - Lamin A/C, located in cytoskeleton, nucleus, cytosol, this protein is part of 
cytoskeletal proteins. 
GNB4 differently expressed in HG-3 as in MEC-1. 
 
As the cells of miR-155 deficient clones (originating from the single cell) were proliferating 
slower compared to unedited cells during routine cell culturing, we have decided to follow 
these observations with advanced approaches. Firstly, we did the standard cell count to assess 









































Fig. 14: The proliferation rate of human CLL cell line HG-3. Cell growth curve of HG-3 cells (ctrl - wt 
and miR-155 deficient clone #4) was determined by cell number count by hemocytometer within 7 days. 
Seeding density at day 0 was 20 000 cells per well. Y-axis shows cell number and X-axis day. Data represent 
the mean of 2 independent experiments (+/-STDEVA). Statistics: t-test, two tailed, unpaired was used, 
p>0.05.  
Fig. 15: The proliferation rate of human CLL cell line MEC-1. Cell growth curve of MEC-1 cells (ctrl - 
wt and miR-155 deficient clone #48) was determined by cell number count by hemocytometer within 7 days. 
Seeding density at day 0 was 20 000 cells per well. Y-axis shows cell number and X-axis day. Data represent 




In both cell growth curves is significantly visible difference in the level of proliferation speed 
between wild-type cells and edited clones. 
According to this finding, we were curious, if the slower cell growth is connected to higher 
occurrence of apoptosis or not. Therefore we performed flow cytometry measurement of cells 
stained with apoptotic protein Annexin V (APC) in period of 7 days. Population of dead cells 





Fig. 16: Viability of HG-3 cells (Evaluation of apoptosis by flow cytometry. HG-3 cells (ctrl and miR-155 
deficient clone #4) were stained by Annexin V/PI (X-axis, Annexin V, APC, and Y-axis, PI in PE-Cy7 
channel). Data were evaluated by Diva software and the measurement was performed with the use of the 









As shows Fig. 16 there is practically no difference in the population of apoptotic and dead 
cells in HG-3 cell line wt vs edited clone #4. Interestingly, MEC-1 cell line shows higher 
abundance population of dead cells in edited clone #48 in comparison to wild type MEC-1.  
Fig. 17: Viability of MEC-1 cells (Evaluation of apoptosis by flow cytometry. MEC-1 cells (ctrl and miR-
155 deficient clone #48) were stained by Annexin V/PI (X-axis, Annexin V, APC, and Y-axis, PI in PE-Cy7 
channel). Data were evaluated by Diva software and the measurement was performed with the use of the 




We worked with two CLL cell lines, both of them with higher expression of miR-155 in 
comparison to the normal healthy B-cells. HG-3 cell line shows lower expression than MEC-1 
that is in concordance with the level of disease stage. We performed nucleofection of these 
cell lines with plasmid containing all sequences for CRISPR/Cas9 system, gRNA and GFP for 
detection (for details see Fig.11 D). Gene editing of MEC-1 cell line was 
performed formerly by Dr. Savvulidi Vargová and the system of gaining mutant cell line 
remained the same. 
1.  By CRISPR/Cas9 tool we created deletion mutant of human B-CLL cell line HG-3 
that do not express miR-155.  
We provided insertion of plasmid by nucleofection, which is electroporation-based 
transfection method enabling transfer of nucleic acids such as DNA or RNA into cells by 
applying a specific voltage and reagents. The survival rate of B-cells after nucleofection and 
flow cytometer cell sorting is generally quite low (Seiffert et al., 2007); we achieved about 1,4 
% of cell survival, gaining one clone with changes in DNA sequence. The deletion of miR-
155 was partially successful as we gained a clone with deletion of six nucleotides in the 
coding region of miR-155, positioned on one strand of DNA, therefore heterozygous clone. 
We assume, that this low effect is also caused by the low level of progression of CLL in HG-3 
cells (intermediate state of CLL), compared to MEC-1 cell line, where the success rate in 
nucleofection and changing the DNA by CRISPR/Cas9 method was higher (4,3 %). Also 
according to Dr. Seiffert, the larger the nucleofected plasmid is, the higher rate of apoptosis 
occurs. In our experiments we observed apoptotic rate around 10 % in both CLL cell lines.  
To avoid technical difficulties, changing of the delivery method may be considered, by 
lentivirus for example (García-Tuñón et al., 2017).  
In order to identify which nucleotides were deleted by CRISPR/Cas9 we performed Sanger 
sequencing of PCR product, which showed the deletion in one strand clearly, in the second 
strand were some changes, but not so clearly identifiable. We would suggest in case of 
gaining more clones and choosing the best for further studies, to perform subcloning of PCR 




2. Explore the impact of miR-155 deletion on HG-3 cell line viability and proliferation. 
Even though the deletion in HG-3 cell line was just partial in coding sequence of miR-
155 and executed in one strand of DNA, the cell growth curve shows, that the number of cells 
grew with difference between wild type and heterozygous clone. Our results provide support 
for our research hypothesis. P-value comes up to 0.07, therefore we can’t reject the null 
hypothesis, but the cell growth curve grows significantly higher in seventh day, which is the 
last day of measurment. If we provided the measurment for longer time, maybe we would 
record lower p-value. On the other hand, cell growth curve of MEC-1 cell line, has significant 
difference, as a result we can confirm, that changes in the DNA sequence of miR-155, and 
deletion of nucleotides lead to slower proliferation of MEC-1 cell line.  
Cell viability 
We made measurment of viability of both cell lines during 7 days by flow cytometry, 
focusing on the number of alive, apoptotic and dead cells (Fig. 8, 9). Cells were stained by 
Annexin V/PI. The number of HG-3 cells was stable throughout the seven days, about 80 % of 
cells was alive, the number started to change at the seventh day, any actual difference between 
control (wild type) and miR-155 heterozygous clone was not detected. These graphs support 
the data from cell growth curve, that during first six days the number of cells doesn’t change 
much. This can be explained by the moderate level of CLL progression. 
MEC-1 cell line showed different outcome, wild type shows high number of alive cells 
throughout the seven days, quite interestingly, the percentage of alive cells is growing after 
fifth day. The results from Day 0 we don’t include in the observation, because of some 
propably technical difficulties, since the same trend occurs in both wild type and clone. MEC-
1 homozygous clone shows different ratio of alive and dead cells, it may be caused by higher 
assumption to die because of genetic changes – thanks to CLL, and „curing“ by lack of miR-
155, which blocks dying of cells. Or, according to data from the beginning of measurement 
(Days 1-3), it can be caused by defrosting of wrong cryotube with already high amount of 
dead cells. 
Conclusion of these viability measurments is, that in HG-3 cell line, the viability actually 
didn’t change. In MEC-1 cell line there are changes, but not provided with enough evidence 
and many factors, which can cause the difference, without any significant influence of the 
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deleting of miR-155. Therefore it would be appropriate to perform this experiment again to 
distinguish what caused the difference. 
3. Comparison of the gene expression profile of HG-3 cells before and after gene editing. 
We performed qRT-PCR for both CLL cell lines, as show Fig. 13. We aligned genes 
by its expression. Expression of these genes in wild type was set as control to the value 1 and 
other genes were compared to this relative value. Genes were aligned by ct value, firstly 
validated targets, in part „A“, in part „B“ are shown genes which may be bona fide targets of 
miR-155 in CLL.  
The most visible difference between HG-3 and MEC-1 cell line is the expression of 
GNB4 gene, in HG-3 there wasn’t any measurable value, on the other hand in MEC-1, its 
expression was significantly higher, therefore we can confirm GNB4 as miR-155 target. In 
comparison, the GNB4 may be part of different pathway in cancerogenesis, according to its 
overexpression in breast cancer cells (B. Wang et al., 2018). The difference in these CLL cell 
lines may be caused by the progressive state of the disease, but presumably the reason may be 
the level of miR-155 expression. As we can see right away at the third column, the expression 
of miR-155 in HG-3 is lower, than wild type, but not distinctively. 
Further expressed gene is hsa-miR-155, as mentioned above, clearly deletion of 6 
nucleotides within the mature sequence of miR-155 located on one DNA strand, is not 
sufficient for complete loss of its function. In MEC-1 cell line this deletion was successful, we 
gained biallelic deletion (homozygous clone), therefore comparison of miR-155 expression in 
clone #48 versus wild type cells is more reliable in MEC-1 cell line than in HG-3 cells. 
The expression of SRSF1 is in HG-3 heterozygous clone slightly higher, than in 
control and significantly lower in MEC-1 homozygous clone, which means, that in CLL this 
gene is likely upregulated by miR-155. Protein encoded by SRSF1 is involved in RNA 
processing. 
SP1 gene, in Fig. 13 named as PU.1, encodes PU.1 transcription factor. As it is direct and 
validated target of miR-155, we supposed its upregulation (in different rate based on deletion 
level of miR-155) in both cell lines after gene editing. PU.1 is confirmed target of miR-155 in 
CLL cells (Huskova et al., 2015; Vargova K et al, 2011 and 2017). Interestingly, expression 
of PU.1 was 0.5 fold in both cell lines after gene editing. This fact could be explained by 
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existence of some compensation molecule, secondary target of miR-155 that could regulate 
PU.1 expression in CLL cells.   
HMGCS1 expression is in HG-3 heterozygous clone and MEC-1 homozygous clone 
slightly higher, than in wild type. This gene encodes catalytical protein 
Hydroxymethylglutaryl-CoA synthase. 
The expression of NSUN5 is in HG-3 heterozygous clone higher, than in control and 
significantly lower in MEC-1 homozygous clone, which means, that in CLL this gene is 
usually upregulated by miR-155. NSUN5 encodes a methyltransferase, which can effect 
expression of genes. 
PDCD4 gene is associated with apoptosis, encodes Programmed Cell Death 4 protein, 
which inhibits translation initiation and acts as tumor supressor. Therefore it’s not surprising, 
that in both HG-3 and MEC-1 cell line this gene is extremely supressed in CLL wild type, 
more in MEC-1 respectively. 
PRKAR1A encodes regulatory subunit of the cAMP-dependent protein kinases. Its 
expression differs in HG-3 heterozygous clone, where it’s two fold higher, than in wild type, 
and it’s expression is slightly lower in MEC-1 homozygous clone. 
CDKN1A encodes a potent cyclin-dependent kinase inhibitor, which binds to 
complexes of cyclin-cyclin-dependant kinase 2 and 4, by this activity it prevents continuing of 
cell cycle to S phase. In HG-3 cell line is this gene  
„Not- validated targets“ a bona fide targets of miR-155 in CLL cells 
HIST1H2AC encodes Histone H2A type 1-C protein, which is part of nucleosome, its 
expression in heterozygous clone of HG-3 cell line, is slightly over the control and in MEC-1 
cell line the expression decreased. 
LDHA is another gene of catalytical protein, Lactate Dehydrogenase A, this enzyme 
catalyzes the conversion of L-lactate and NAD to pyruvate and NADH during anaerobic 
glycolysis. Physiological expression of this protein is higher in oxygen-poor environment. 
Otherwise, even in oxygen-rich environment, this enzyme is highly expressed in cancer cells 
(Arseneault et al., 2013). Therefore we expected higher expression of LDHA in unedited HG-
3 and MEC-1 cell lines. Surprisingly, based on our results, the expression of LDHA was in 
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both cell lines about control level. Therefore we could assume, that this protein is not affected 
by miR-155 expression in CLL cells. 
THRAP3 encodes protein, which is involved in pre-mRNA splicing and can trigger 
mRNA decay. This gene is more expressed in heterozygous clone of HG-3 cell line than in 
wild type, on the other hand, in MEC-1 cell line homozygous clone it’s downregulated. This 
difference could indicate to changes in mRNA splicing due to different expression of miR-
155 in edited CLL cells. 
RRP15‘s level of expression in HG-3 clone is about 0.5 fold, in MEC-1 clone this 
gene is about of control’s level of expression, which means, that normally is this gene in CLL 
cell line upregulated due to miR-155 overexpression. 
PSMG2 encodes a chaperone protein. In HG-3 clone this gene is upregulated, on the 
other hand in MEC-1 clone downregulated. Again, we could assume that this difference is due 
to different miR-155 expression in edited CLL cells. 
VIM encodes protein Vimentin, which is part of cytoskeletal intermediate filaments. 
Its expression is upregulated in HG-3 heterozygous clone, but at the same level as wild type in 
MEC-1 cell line. 
TMSB4X is also gene encoding protein connected to cytoseleton, but as part of actin-
associated proteins. In HG-3 cell line clone it’s two times upregulated, in MEC-1 the level of 
expression is at the same level as wild type. 
MX1 gene (Interferon-induced GTP-binding protein) is 0.5 - 1.0 fold upregulated in 
both HG-3 and MEC-1 cell line. 
ISG15 encodes ubiquitin-like protein, which conjugates to intracellular target proteins. 
It has also function of chemotactic activity towards neutrophils. This gene is upregulated (1.0-
1.5 fold) in both clones. 
LMNA shows also surprising level of expressions. In HG-3 cell line the level is highest 
which was measured within all genes (2 fold), on the other hand in MEC-1 cell line the 
expression is lower, but close to wild type level. LMNA encodes Lamin, which is also part of 
cytoskeleton proteins group. 
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We performed qPCR of 20 different genes, beside hsa-miR-155, all of them with 
different function, but some of them can be separated into small groups according based on 
their function. Some results gained from HG-3 heterozygous clone are in correlation with the 
level of expression of same genes in MEC-1 cell line, but some differ showing also quite the 
opposite. Because of these results and also expression of hsa-miR-155 gene, which was 
supposed to be downregulated, ideally to minimum, the results shouldn’t be taken that strong. 
If we look at expression of some groups, we may find some interesting results, for 
example the level of expression of cytoskeleton connected group that consists of PNN, VIM, 
LMNA and TMSB4X. If we just focus on results measured in MEC-1 cell line (reason 
mentioned above), we may see that the level of expression in homozygous clone is mostly the 
same as wild type expression level, or slightly decreased, which means, that hsa-miR-155 
doesn’t affect their expression. Because also these genes are in group of not-confirmed 
targets, these results support that they are not targets. On the website rnacentral.org is VIM 
listed as target of hsa-miR-155, verified by microarrays. But our results show the opposite. 
In group of catalytical proteins we have HMGCS1 -  validated target and LDHA – not 
validated target. According to our measurment HMGCS1 is affected by miR-155 expression, 
but the level of LDHA is the same as control, therefore we assume that it’s not a target of hsa-
miR-155 in CLL cells. 
PDCD4 and CDKN1A are genes connected to cell cycle or apoptosis, both of them are 
validated targets of miR-155, which is also supported by our results. 
To answer the specific aims of the thesis: 
We detected differences in the transcriptom of both cell lines, in HG-3 those were 
mostly higher expressions of both, novel and validated targets, which seems to be misleading, 
according not complete, or successful deletion of hsa-miR-155 in this cell line. In MEC-1 cell 
line we observed both up and down regulations, most of validated targets were upregulated. In 
the group of novel or potential targets there were two genes upregulated (TMSB4X, MX1), but 
most of them showed no changes in expression or just slightly lower, than control. Those 
which were at the same level as control are probably not targets of hsa-miR-155. 
Even though the results of gene expression in HG-3 cell line were not strong enough 
for deciphering which genes are targets of hsa-miR-155, the incomplete deletion within its 
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sequence impairs cell growth observed in period of one week. Simmilar results were achieved 
with MEC-1 cell line, in miR-155 deficient clone #48. 
All the information according to gene coding and function of proteins were taken from 







In this thesis we performer CRISPR/Cas9 gene editing of hsa-miR-155 in HG-3 cell 
line, which lead to gaining heterozygous clone. Later we executed Further experiments, such 
as measurement of the cell proliferation and viability of HG-3 and MEC-1 cell lines. We 
gained different levels of expressed target genes of hsa-miR-155 by qRT-PCR in both of these 




7. List of Abbreviations 
 
CDKN1A Cyclin Dependent Kinase Inhibitor 1A 
CLL chronic lymphocytic leukemia 
DMSO dimethylsulfoxi 
FACS fluorescence activated cell sorting 
FBS fetal bovine serum 
FCR combination of drugs: fludarabine, cyclophosphamide, rituximab 
GNB4 G Protein Subunit Beta 4 
HIST1H2AC Histone H2A type 1-C 
HMGCS1 Hydroxymethylglutaryl-CoA synthase 
ISG15 ISG15 Ubiquitin Like Modifier 
LDHA Lactate Dehydrogenase A 
LMNA Lamin A/C 
miR-155 microRNA - 155 
MX1 MX Dynamin Like GTPase 1  
NSNU5 NOP2/Sun RNA Methyltransferase 5 
PBS phosphate buffered saline 
PDCD4 Programmed Cell Death 4 
PNN Pinin, Desmosome Associated Protein  
PRKAR1A Protein Kinase CAMP-Dependent Type I Regulatory Subunit Alpha 
PSMG2 Proteasome Assembly Chaperone 2  
PU.1 Transcription factor PU.1 
qPCR quantitative polymerase chain reaction 
RPS29 Ribosomal Protein S29 
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RRP15 Ribosomal RNA Processing 15 Homolog 
SRSF1 Serine And Arginine Rich Splicing Factor 1 
THRAP 3 Thyroid Hormone Receptor Associated Protein 3 
TMSB4X Thymosin Beta 4 X-Linked 
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